The discovery of the immune checkpoint mechanism has contributed greatly to recent
advances in cancer treatment. The anticytotoxic T lymphocyte-associated protein 4 antibody …

The position of immunotherapy as a pillar of systemic cancer treatment has been firmly
established over the past decade. Immune checkpoint inhibitors are a welcome option for …

Simple Summary Immune checkpoint inhibitors represent a promising treatment choice in
many kind of tumours, including hepatocellular carcinoma (HCC). In this review, we provide …

Clinical trials of antibodies targeting the immune checkpoint inhibitors programmed cell
death 1 (PD-1), programmed cell death ligand 1 (PD-L1), or cytotoxic T-lymphocyte …

The implementation of immune checkpoint inhibitors (ICI) into the clinical management of
different malignancies has largely changed our understanding of cancer treatment. After …

Hepatocellular carcinoma (HCC) is the most common liver cancer with high morbidity and
mortality worldwide. Systemic treatments with several multi-targeted tyrosine kinase …

Hepatocellular Carcinoma (HCC) is one of the most common malignancies, and its
incidence and mortality are increasing worldwide. Cancer immunotherapy has …

The introduction of immunotherapies has been a major development in the treatment of
many advanced cancers, including hepatocellular carcinoma (HCC). We are entering a new …

Abstract Treatment of patients with hepatocellular carcinoma (HCC) in the advanced stage
remains a great challenge, with very few drugs approved. After decades of failure of immune …

Several anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies (Table 1) are currently being
investigated, alone and in combination, for the treatment of hepatocellular carcinoma (HCC) …